Skip to main content

Table 1 Experimental vector vaccines against Mycoplasma hyopneumoniae tested in mice.

From: Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs

Antigen Vector Route Nb of vaccinations Humoral response CMI responsea Other/comments References
Serum BALFb  
NrdF (R2) Salmonella Typhimurium aroA SL3261 Oral 3 No IgG, no IgA IgA, no IgG    [75]
P97 (R1) Salmonella Typhimurium aroA CS332 (pro- and eukaryotic plasmid) Oral 2 No No IFN-γ   [76]
NrdF (R2) Salmonella Typhimurium aroA CS332(pro- and eukaryotic plasmid) oral 2 No No IFN-γ response (only with eukaryotic vector)   [77]
P97 (R1) Adenovirus IM or IN 2 IM / IN: IgG
IM: IgG2a/IgG1 = 4
IN: IgG2a/IgG1 = 1
IM /IN: IgG, IgG1, IgG2a
IN: IgA
  Serum and BAL inhibited growth of M. hyopneumoniae [78]
P36 Actinobacillus pleuropneumoniae SLW36 IM 2 IgG     [79]
P97c Adenovirus IM 2 IgG, IgG1, IgG2a, IgG2b, IgG3
IgG2a/IgG1 ≈ 1
   P97c may act as immunopotentiator [80]
P97R1, P46 Bacillus subtilis IN 2 IgG IgA IFN-γ, Il-4   [81]
  1. IM, Intramuscular; IN, Intranasal.
  2. aCMI cell-mediated immune responses were tested by stimulation of splenocytes.
  3. bBALF bronchoalveolar lavage fluid.